Information Provided By:
Fly News Breaks for September 19, 2017
PCRX
Sep 19, 2017 | 20:00 EDT
BMO Capital analyst Gary Nachman says that while sales of Pacira Pharmaceuticals' Exparel were up in August relative to July, the drug continues to track well below consensus expectations for Q3. According to Symphony, August sales were up 7.7% year-over-year and improved from July, Nachman tells investors in a research note following tonight's data release. He points out, however, that Exparel sales per selling day were actually down 0.4% versus the prior month. Symphony data have not always been completely reliable in the past, the analyst admits. He keeps a Market Perform rating on Pacira.
News For PCRX From the Last 2 Days
There are no results for your query PCRX